Workflow
中国医疗集团(08225) - 2021 Q3 - 季度财报
C HEALTH GPC HEALTH GP(HK:08225)2021-11-11 14:37

Financial Performance - For the nine months ended September 30, 2021, the group recorded revenue of approximately RMB 55,829,000, an increase of about 8.5% compared to the same period in 2020[5]. - For the same period, the group reported a profit before tax of approximately RMB 31,059,000, a decrease of about 16.1% compared to the prior year[6]. - Basic earnings per share for the nine months were approximately RMB 2.59 cents, down about 21.5% from the same period in 2020[7]. - The gross profit for the nine months was approximately RMB 44,064,000, compared to RMB 38,622,000 in the same period last year[11]. - The total comprehensive income for the nine months was RMB 25,808,000, compared to RMB 32,799,000 in the same period last year[11]. - Total revenue for the period increased by 8.5% compared to the same period in 2020, with total revenue for the three months ended September 30, 2021, decreasing by 18.00% compared to the same period in 2020[20]. - Basic earnings per share were approximately RMB 25,808,000, compared to RMB 32,799,000 for the same period in 2020, with a weighted average number of ordinary shares of approximately 995,351,660[23]. - The group achieved a pre-tax profit of approximately RMB 31,059,000, down from RMB 37,023,000 in the same period last year, with net profit approximately RMB 25,808,000 compared to RMB 32,799,000 last year, primarily due to the sale of three wholly-owned subsidiaries which generated a transfer gain of RMB 10,224,000 last year[34]. Dividends - The board of directors proposed not to declare any dividend for the nine months ended September 30, 2021[8]. - The company has not recommended any dividend payments for the period[27]. - The board does not recommend the distribution of dividends for the nine months ended September 30, 2021, consistent with the previous year[36]. Operating Expenses - The operating expenses for the nine months were RMB 31,070,000, down from RMB 37,061,000 in the previous year[11]. - Administrative expenses rose by 10.86% compared to the same period in 2020, amounting to RMB 2,728,000 for the three months ended September 30, 2021[21]. Business Strategy and Development - The group aims to become a comprehensive service provider under an internet architecture in the healthcare sector[16]. - The company has established a biobank testing laboratory to support clinical research, particularly for antiviral drug studies[29]. - The company launched two new business models: "RWS-Therapy" and "D-CRCO," aimed at redefining research-based treatment and commercialization through big data[30]. - The company has formed partnerships with top medical institutions in cities like Beijing, Shanghai, and Guangzhou to enhance digital healthcare services[30]. - The company is exploring a comprehensive digital healthcare service model that integrates research, rehabilitation, and medical tourism[31]. - The group is enhancing its marketing capabilities and expanding its market network, focusing on a value chain business model in the local market with its sub-brands[35]. - The board will review and evaluate potential projects or investments to enhance business performance and shareholder returns[35]. Financial Position and Investments - The group has not made any significant investments during the reporting period, similar to the situation as of December 31, 2020[37]. - As of September 30, 2021, the group had no unrecorded contingent liabilities, maintaining the same status as of December 31, 2020[38]. - The company has not disclosed any significant future investment or capital asset plans beyond what has been reported[39]. Shareholding Structure - Winsland Agents Limited holds 349,368,873 shares, representing 35.10% of the company's equity[55]. - Venturepharm Holdings Inc. has a beneficial ownership of 149,432,583 shares, accounting for 15.01% of the equity[55]. - Bright Excel Assets Limited, a wholly-owned subsidiary of Venturepharm Holdings Inc., holds 91,915,181 shares, which is 9.23% of the equity[57]. - The company has a controlled corporation interest of 241,347,764 shares, which is 24.25% of the equity[55]. Governance and Compliance - The company has not appointed a CEO, with daily management handled by executive directors and senior management[60]. - The audit committee, consisting of three independent non-executive directors, has reviewed the unaudited consolidated results for the period[62]. - The company maintains sufficient public float as of the report date[64]. - The company has complied with the GEM Listing Rules regarding securities trading standards during the reporting period[61]. - The board emphasizes high-quality governance and transparency to shareholders[60]. Miscellaneous - The group has not recognized any revenue from contract clinical research services during the period[20]. - There were no purchases, sales, or redemptions of the company's listed shares by the company or any of its subsidiaries during the nine months ended September 30, 2021[42]. - The report was published on November 11, 2021, and will be available on the GEM website for seven days[66].